On July 3, WuXi Biologics rose 3.4% in regular trading, trading at HK$37.1/share, with turnover of HK$829 million.

On the news front, the company has maintained an aggressive buyback pace, accumulating over 37.108 million shares repurchased since May 26 at a total cost of approximately HK$1.172 billion, signaling management confidence in intrinsic value. Additionally, the company recently announced that three factories at its Wuxi production base passed Brazil ANVISA GMP certification with zero observations, further validating its global commercial manufacturing capabilities.

Within the Life Sciences Tools & Services sector, peer stocks showed broad strength. WuXi XDC rose 5.1%, XtalPi gained 3.34%, and GenScript Biotech advanced 2.59%, reflecting notable sector-wide momentum. Separately, China International Capital Corporation maintains an Outperform rating on the stock with a target price of HK$48, citing the company's expanding late-stage pipeline of 982 total projects including 78 Phase III and 25 commercial-stage programs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)